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Intracellular screening of a peptide library to derive a 
potent peptide inhibitor of α-synuclein aggregation. 
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Background: Deposition of α-syn into 
Lewy Bodies is considered the primary 
event in Parkinson’s disease. 
Results: A peptide selected via PCA library 
screening functions by inhibiting fibril 
formation 
Conclusion: Semi-rational design 
combined with intracellular PCA is an 
effective methodology to develop α-syn 
aggregation antagonists 
Significance: The technique can be applied 
to a number of diseases from Parkinson’s to 
Alzheimer’s. 
 
ABSTRACT 
 
Aggregation of α-synuclein (α-syn) into toxic 
fibrils is a pathogenic hallmark of 
Parkinson’s disease (PD). Studies have 
largely focused on residues 71-82, yet most 
early onset mutations are located between 
residues 46-53. A semi-rationally designed 
209,952 member library based entirely on 
this region was constructed, containing all 
wild-type residues and changes associated 
with early onset PD. Intracellular cell-
survival screening and growth competition 
isolated a 10-residue peptide antagonist that 
potently inhibits α-syn aggregation and 
associated toxicity at 1:1 stoichiometry. This 
was verified using continuous growth 
measurements, and MTT cytotoxicity 
studies. Atomic force microscopy and 
circular dichroism on the same samples 
showed a random-coil structure and no 
oligomers. A new region of α-syn for 
inhibitor targeting has been highlighted, 
together with the approach of using semi-
rational design and intracellular screening. 
These peptides are candidates for 
modification into drugs capable of slowing or 
even preventing the onset of PD. 
 
Deposition of α-synuclein (α-syn) into 
neuronal inclusions known as Lewy bodies is 
considered the causative agent in the 
pathogenesis of Parkinson’s disease (PD), a 
debilitating disease which results principally in 
rigidity, tremor and slowness of movement and 
accounts for approximately 15% of all 
dementias (1,2). The accumulation of toxic 
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Lewy bodies in the cytoplasmic space of 
dopaminergic neurons in the substantia nigra 
pars compacta region of the brain leads to cell 
death, decreased dopamine levels, and 
ultimately the symptoms of the disease. There 
is a substantial and growing body of evidence 
implicating α-syn in PD (3), including:  i) 
synthetic α-syn rapidly aggregates into β-sheet 
rich fibrils similar to those found in Lewy 
bodies; ii)  rare familial mutations that increase 
fibril aggregation rates and toxicity lead to 
early onset PD; iii) α-syn gene duplications lead 
to increased protein expression and therefore 
accelerate disease onset, and iv) α-syn 
oligomers are toxic to therapeutically relevant 
cells in culture.  To intervene in PD we have 
utilised a novel intracellular screen to identify 
peptides capable of binding to and reducing the 
associated toxicity of a-syn aggregation. Our 
approach has the potential to address recent 
findings that suggest that pre-fibrillar oligomers 
are the toxic species (4).  
There is a wealth of experimental data 
demonstrating that region 71-82 is responsible 
for the aggregation of the full length 140 amino 
acid protein(5-7). Indeed, numerous groups 
have used this region as a starting point for the 
design of inhibitors. This has included non-
modified peptides (8) and N-methylated 
peptides (9). Given the interest in this region 
and its requirement for aggregation of the full-
length protein, many groups have focused their 
efforts on producing libraries based on this 
scaffold. However, of the known point 
mutations in the α-syn gene associated with 
early onset PD, three (E46K, H50Q, A53T) are 
located between residues 46-53 with the fourth 
(A30P) located in close proximity. More 
recently a fifth mutation, G51D, has been 
identified (10). This region and the residues 
within are clearly important in modulating 
amyloid formation such that toxicity associated 
with the α-syn protein becomes increased, with 
the changes leading to decreased α-helicity, 
increased β-sheet propensity, and either an 
increase in the rate or in the number of 
oligomers that are formed (11-14).  
Here we have generated peptide 
inhibitors using a multiplexed intracellular 
Protein-fragment Complementation Assay 
(PCA) library screening system (15,16) 
followed by direct imaging of the samples. 
Successfully selected peptides must bind α-syn 
to reduce amyloid cytotoxicity and confer 
bacterial cell survival. During PCA no 
assumptions are therefore made regarding the 
mechanism of action or the oligomeric state of 
α-syn that becomes populated. The only 
prerequisite for peptide selection is that i) 
peptides bind to α-syn such that the split 
reporter enzyme is recombined and ii) that the 
result is lower toxicity such that cell survival is 
facilitated. In addition, the PCA approach is 
predicted to select peptides that are resistant to 
degradation by bacterial proteases, to be 
soluble, non-toxic, and to be target specific in 
the presence of other cytoplasmic proteins. 
Using α-syn45-54 as a template for our 
library design we have created a 209,952 
member peptide library ten amino acids in 
length that spans residues 45-54 containing the 
wild-type 45-54 sequence, including residue 
options corresponding to E46K, H50Q, and 
A53T which when mutated give rise to early-
onset PD.  PCA has been used to screen the 
peptide library for an interaction with wild-type 
α-syn. The effectiveness of an amyloid-PCA 
selected peptide has been subsequently tested 
by performing four key experiments upon the 
same sample. These experiments are a 
continuous amyloid growth assay, monitored 
using ThT fluorescence, circular dichroism, to 
report on changes in β-sheet content, and 
atomic force microscopy and SDS-PAGE 
analysis, to directly image any reduction in 
fibril load and changes in the fibril morphology. 
We find the peptide derived using this approach 
to be capable of binding to the disease relevant 
wild-type α-syn and reducing associated 
amyloid formation by over 90%. This study has 
both successfully verified the methodology for 
producing anti α-syn aggregation peptide 
inhibitors using the amyloid-PCA approach as 
well as produced a lead peptide sequence that is 
expected to provide a scaffold for future drug 
candidates. 
Our data collectively indicate that the PCA 
derived 45-54W sequence is able to prevent the 
aggregation of wild-type α-syn at a 
stoichiometry of 1:1. The ThT fluorescence 
signal associated with amyloid formation does 
not progress beyond ~8% of the original 1:0 
sample. Atomic force microscopy experiments 
show that in the same continuous growth 
samples there is a striking loss in the number of 
fibrils relative to the 1:0 samples. MTT 
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cytotoxicity studies using the same samples 
show a reduction in cell death of 65-85% 
compared to α-syn in isolation. Finally, circular 
dichroism experiments using samples taken 
from the same continuous growth experiment 
once again show that the conversion from a 
random coil structure to a β-sheet rich structure 
is almost completely abolished in the 1:1 
sample. At a molar ratio of 1:0.5 the formation 
of the mature amyloid fibrils found in the 1:0 is 
slowed but ultimately not prevented (see Figure 
3a). At stoichiometries of 1:0.1 and 1:001 the 
rate of amyloidosis is not significantly lowered 
relative to the 1:0 sample. 
 
EXPERIMENTAL PROCEDURES 
 
Primers and library cloning: Primers were 
designed such that the desired library could be 
generated using overlap-extension PCR. Bases 
overlapped in a non-randomised region of the 
primers to give an approximate annealing 
temperature of 66°C. Correct amplification was 
enabled via an elongated reverse primer and 
verified by agarose gel electrophoresis. The 
correct PCR product was then digested using 
NheI and AscI restriction enzymes for 
subcloning of the library into the pES230d 
vector (restriction enzyme recognition sites 
shown). Primer sequences used were: Forward 
Primer: 5’- C TGG GCT AGC RAA VAW 
GBG VTT VTT VAW GBG VTT RHA RCC 
GGC GCG CCG CTA GAG GCG -3’; Reverse 
Primer: 5’- T TTT TTT TTA TAA TAT ATT 
ATA CGC CTC TAG CGG CGC GCC -3’. An 
additional 30 residues on the 5’ end of the 
reverse primer was used to observe the correct 
PCR product prior to restriction digestion. 
 
Single Step Selection PCA – E.coli XL-1 cells 
were used for construction and cloning of 
libraries as described previously (16-18). Firstly 
pES300d–α-syn target and pREP4 (Qiagen; for 
expression of the lac repressor protein) were 
co-transformed into BL-21 gold cells 
(Stratagene) and plated onto LB agar with the 
appropriate antibiotics (Kan and Cm). These 
cells were next made electrocompetent before 
transformation with pES230d–45-54 library 
plasmid. Transformed cells were plated onto 
three different media; 1/20
th
 of the cells were 
plated onto LB agar with three antibiotics (Kan, 
Amp, and Cm) as a positive control of 
transformation efficiency. A further 1/20
th
 of 
the solution was plated onto M9 minimal 
medium agar containing 1μg/ml trimethoprim 
and the same three antibiotics as a negative 
control. Finally, the remaining 90% of 
transformed cells were plated onto M9 minimal 
agar in the presence of the three antibiotics, 
1μg/ml trimethoprim, and 1 mM IPTG 
(isopropyl-β-D-thiogalactopyranoside), to 
induce expression of the two DHFR fragment 
fused peptides). This single-step PCA selection 
led to approximately 200 colonies from the 
initial library of 209,952 meaning that >99.9% 
of all library members are removed at this stage 
owing to their inability to bind α-syn. 
 
Competition Selection PCA - To increase 
selection stringency, growth competition 
experiments were undertaken. Selected colonies 
were pooled from the plate and grown in M9 
minimal media under selective conditions 
(containing Kan, Amp, Cm, trimethoprim and 
IPTG) and serially diluted over 5 passages (p1-
p5). Using these sequential rounds of 
competition selection, subtle differences in 
growth rate can become amplified, increasing 
the stringency of selection relative to the single-
step method. Competition selection therefore 
allows the most effective 1-2 sequences to be 
isolated from the ~200 α-syn binders initially 
identified during single step selection. At each 
passage glycerol stocks were prepared and 
sequencing results were obtained (Source 
bioscience, Nottingham) for DNA pools as well 
as individual colonies. For each passage, 50 μl 
of liquid culture was added to 50 ml of fresh 
M9 minimal media, resulting in an approximate 
OD600 of 0.01. Cells were incubated at 37°C 
until an OD600 of ~0.4 was reached (typically 2-
3 days), before moving to the next passage.   
 
Protein expression and purification – Wild-
type α-syn was synthesized by overexpression 
in E.coli (BL21) strain using a small ubiquitin 
related modifier (SUMO) fusion (19). SUMO 
modulates protein structure and function by 
covalently binding to the lysine side chains of 
the target protein to enhance expression and 
solubility of the α-syn protein. E.coli BL21 
competent cells were transformed with pET21b 
plasmid construct and grown on Luria Bertani 
(LB) plates containing Amp and Cm and grown 
overnight. Single colonies were next picked, 
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inoculated in LB broth containing Amp and Cm 
and shaken at 37°C. These cultures were then 
used to inoculate 2 litres of liquid Luria broth 
containing Amp and Cm and grown to the mid 
log phase growth (OD600 = 0.6-0.8) before 
being further induced by 1mM IPTG for 3 
hours at 37°C. Cells were obtained by 
centrifugation at 4000rpm 20 minutes at 4°C in 
a Sorvall RC superspeed centrifuge. Cell pellets 
were then resuspended in binding buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, pH: 8) and homogenised using a 
magnetic stirrer for 15 minutes on ice followed 
by sonication (40% amplification). Lysed cells 
were next centrifuged at 18,500 rpm for 20 
mins at 4°C using an SS-34 rotor (Sorvall RC 
superspeed centrifuge). The supernatant 
containing the protein was stored at -20°C.  
Purification of the fusion protein was 
achieved by applying the supernatant from the 
cell lysate on to an Ni-NTA affinity column at a 
flow rate of 3 mL/min three times to allow the 
protein to bind. The column was next washed 
with 40 mL wash buffer (50 mM NaH2PO4, 300 
mM NaCl, 30 mM imidazole, pH: 8) and the 
protein was eluted using elution buffer (50mM 
NaH2PO4, 300mM NaCl, 500 mM imidazole, 
pH: 8). The protein sample was then exchanged 
to cleavage buffer (20 mM Tris, 0.5 mM DTT, 
pH 8.0) using a PD10 desalting column. The 
6
His-SUMO tag was removed using specific 
SUMO protease-UlP1 enzyme (1mg/mL for 
10mg/mL of target protein) at 30°C for 16 
hours. 
The 
6
His-SUMO was finally removed 
using a size-exclusion column. G-75 column 
was washed 3 times with 10mM MES, 150 mM 
NaCl, pH 8.0. The protein was concentrated to 
2mL, injected to the column and fractions were 
eluted according to their molecular weight. 
Finally, SDS-PAGE was used to determine the 
purity of the α-syn and to verify that the 
expected molecular mass different fractions 
containing α-syn (14.7 kDa), SUMO protein 
(12.2 kDa), and SUMO protease (27 kDa). The 
correct mass of α-syn was further confirmed 
using electro-spray mass spectrometry. The 
protein concentration was finally determined in 
a Varian cary-50 spectrophotometer. The 
purified protein was lyophilized using a freeze 
drier and stored at -80
0
C. 
 
Monomerisation of Protein for aggregation 
studies - In order to monomerise the protein 
prior to aggregation experiments; 1mL of 
hexafluoro-2-propanol (HFIP) was added to 
2mg of lyophilized peptide. This was next 
vortexed for approximately 2 minutes to fully 
dissolve the peptide, followed by sonication at 
25
0
C for 5 minutes in a water bath sonicator. 
HFIP was allowed to evaporate completely 
under a regulated stream of air. The process 
was repeated  3 times, followed by dissolution 
of peptide sample in double distilled water, 
vortexing for 3 minutes and lyophilization for 
further use (9). 
 
Peptide synthesis – Rink amide 
ChemMatrixTM resin was obtained from PCAS 
Biomatrix, Inc. (St.-Jean-sur-Richelieu, 
Canada); Fmoc-l-amino acids and 1H-
Benzotriazol-1-yloxy)(dimethylamino)-N,N-
dimethylmethaniminium hexafluorophosphate 
(HBTU) were obtained from AGTC 
Bioproducts (Hessle, UK); all other reagents 
were of peptide synthesis grade and obtained 
from Thermo Fisher Scientific (Loughborough, 
UK). Peptide 45-54W was synthesized on a 
0.1-mmol scale on a PCAS Biomatrix
TM
 Rink 
amide resin using a Liberty Blue
TM
 microwave 
peptide synthesizer (CEM; Matthews, NC) 
employing Fmoc solid-phase techniques (for 
review see (20)) with repeated steps of coupling 
and deprotection and washing (4 × 5 ml 
dimethylformamide). Coupling was performed 
as follows: Fmoc amino acid (5 eq), HBTU (4.5 
eq), and diisopropylethylamine (10 eq) in 
dimethylformamide (5 ml) for 5 min with 20-
watt microwave irradiation at 90°C. 
Deprotection was performed as follows: 20% 
piperidine in dimethylformamide for 5 min with 
20-watt microwave irradiation at 80°C. 
Following synthesis, the peptide was acetylated 
(acetic anhydride (3 eq) and 
diisopropylethylamine (4.5 eq) in 
dimethylformamide (2.63 ml) for 20 min) and 
then cleaved from the resin with concomitant 
removal of side chain-protecting groups by 
treatment with a cleavage mixture (10 ml) 
consisting of TFA (95%), triisopropylsilane 
(2.5%), and H2O (2.5%) for 4 h at room 
temperature. Suspended resin was removed by 
filtration, and the peptide was precipitated 
using three rounds of crashing in ice-cold 
diethyl ether, vortexing and centrifugation. The 
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pellet was then dissolved in 1:1 MeCN/H2O 
and freeze-dried. Purification was performed by 
RP-HPLC using a Phenomenex Jupiter Proteo 
(C12) reverse phase column (4 μm, 90 Å, 10 
mm inner diameter × 250 mm long). Eluents 
used were as follows: 0.1% TFA in H2O (A) 
and 0.1% TFA in MeCN (B). The peptide was 
eluted by applying a linear gradient (at 3 
ml/min) of 20% to 60% B over 40 min. 
Fractions collected were examined by 
electrospray mass spectrometry, and those 
found to contain exclusively the desired product 
were pooled and lyophilized. Analysis of the 
purified final product by RP-HPLC indicated a 
purity of >95%.  
 
Peptide preparation - Stock solutions of 1mM 
concentration of the inhibitor and control 
peptides were dissolved in ultrapure water. At 
this concentration, a 2-200 fold excess of that 
used in experiments, no aggregation or 
precipitate was observed. In addition, 
bioinformatics tools  (e.g. Waltz (21), 
Amylpred (22), Pasta (23), Zyggregator (24), 
and Tango (25)) did not predict the peptide to 
contain amyloidogenic sequences or aggregate 
in isolation. Lastly dye-binding experiments 
demonstrate that this sequence does not bind 
ThT or aggregate and form random-coil like 
species in isolation using CD (Figures 3 and 4).  
 
Continuous growth ThT Experiments - The 
provided winner was lyophilized in the molar 
concentration of target protein and inhibitory 
peptide as 1:1. The reaction mixture containing 
450μM wild-type α-syn and inhibitory peptide 
was incubated in 90µM ThT, 10mM Phosphate 
buffer (pH 7.0), 100mM KF and 0.05% NaN3 
at 37
0
C with continuous mixing using a 
magnetic flea in an LS55 fluorescence 
spectrophotometer (Perkin Elmer) for 4500 
minutes (75 hours). The same experiment was 
repeated three times for both 1:0 and for 45-
54W containing solutions at a variety of 
stoichiometries, as well as 1:1 molar ratios with 
the control peptides 45-54wt and 71-82W. The 
PCA winner 45-54 peptide was lyophilized in 
aliquots of different molar concentrations of 
target protein and inhibitory peptide ranging 
from 1:0.01, to 1:1.  
 
Circular Dichroism Experiments - Far-UV 
circular dichroism (CD) spectra were recorded 
on an Applied Photophysics Chirascan at 20 °C 
using the same samples from the continuous 
growth ThT experiments. Spectra were 
recorded over the 200-300 nm range at a scan 
rate of 10 nm/min with step size of 1 nm. 
Spectra were recorded as the average of three 
scans. Peptide (10 μM in 10 mM Potassium 
Phosphate buffer pH 7.4) was added to a 0.1 cm 
cuvette (Hellma). Spectra were recorded as raw 
ellipticity. 
 
Atomic force microscopy experiments - 
Samples were imaged in noncontact mode 
using a XE- 120 Atomic Force Microscope 
(Park Systems, South Korea). NSC 15 silicon 
nitride cantilevers with a spring constant of 40 
N/m were used for imaging at a scan rate of 1.0 
Hz and a resolution of 256 x 256 pixels. All 
images were taken at room temperature. The 
AFM data were taken from continuous growth 
experiments. A 5 μL sample was taken from the 
450 μM α-syn continuous growth experiment 
and placed on freshly cleaved mica (thickness 
0.3 mm). Following adsorption of the protein 
aggregates (2 min), the mica was washed with 5 
mL of double distilled water. Excess water was 
removed and the samples were dried using a 
stream of nitrogen gas. Samples were 
immediately analyzed by AFM. The image files 
were examined using WSxM v5.0 (Nanotec 
Electronica S.L.) and flattened before 
processing (26).  
 
3-(4,5.Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide (MTT) Cell-
Toxicity Assay - MTT experiments were 
undertaken using Rat phaeochromocytoma 
(PC12) cells to assess cytotoxicity effect of α-
syn. PC12 cells are known to be particularly 
sensitive and their use in this assay is well 
established (27). The MTT Vybrant® MTT 
Cell Proliferation Assay Kit (Invitrogen) was 
used to measure the conversion of the water 
soluble MTT dye to formazan, which is then 
solubilized, and the concentration determined 
by a purple colour change monitored via 
absorbance measurement at 570 nm. The 
change in absorbance can be used as an 
indicator of the PC12 cell health in the assay. 
The assay was performed with 5 μM α-syn and 
peptide stoichiometry corresponding to 1:1 (5 
μM).  PC12 cells were maintained in RPMI 
1640 +2mM glutamine medium mixed with 
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10% horse serum, 5% foetal bovine serum, 
supplemented with a 20mg/mL gentamycin. 
Cells were transferred to a sterile 96-well plate 
with 30,000 cells per well and experiments 
performed in triplicate. A required volume of 
peptide and target solutions was added to PC12 
cells. A total of 100 μL of PC12/RPMI media 
combined with an appropriate volume of 
peptide/ α-syn target mixture (5 μM peptide + 
5μM α-syn target) was transferred to a 96 well 
microtitre plate. Since the samples contain 
90µM ThT, controls of PC12 cells and α-syn 
alone, both with and without ThT were 
undertaken. These were incubated for 24 h at 
37 °C, 5% CO2, prior to the addition of the 
MTT dye. A total of 10 μL of the dye was 
added to each well and incubated for a further 
4h at 37 °C, 5% CO2. A total of 100 μL of the 
DMSO was then added to each well and was 
allowed to stand for 10 minutes. The 
absorbance was measured at 570 nm using a 
Berthold Tristar LB942 plate reader.  
 
SDS-PAGE – Gel analysis was carried out 
using 15% Tris-bis acrylamide gels operated at 
a constant voltage of 150 V. The running buffer 
was 25mM Tris-HCl, 193 mM glycine, and 
0.1% SDS (pH 8.3). 3 µL of 450 µM α-syn 
along with peptides at different stoichiometries 
were mixed with 7 µL of loading buffer 
containing 50 mM Tris-HCl (pH 6.8), 1% SDS, 
5% glycerol, and 25% bromophenol blue. 10 
µL of each sample was then loaded in each 
well. The gel was stained using 0.1% 
Coomassie blue R250. 
 
RESULTS 
 
α-syn 45-54 library generation – PCA was 
undertaken with full length α-syn1-140 target 
using a library based on the α-syn45-54 region in 
which three of the four α-syn mutations 
associated with early onset PD are located 
(KEGVVHGVAT; wild-type 45-54). Unlike α-
syn71-82, this is not a region of the molecule 
known to aggregate into toxic fibrils in 
isolation (28-30) and therefore has not been 
exploited as a starting point for deriving α-syn 
binders capable of inhibiting aggregation. The 
library incorporated the wild-type sequence 
while introducing two, three or six residue 
options at each of the ten amino acid positions 
(see Figure 1). This corresponded to a library 
size of 209,952. Single step selection on M9 
plates was undertaken followed by competition 
selection in M9 liquid media, resulting in one 
clean sequencing result by passage six; 
KDGIVNGVKA (Figure 2). 
 
Peptide characterization – PCA derived 
peptide sequences (Figure 1) were synthesized 
and characterised using a number of 
experiments that included thioflavin-T (ThT) 
dye binding, circular dichroism (CD), atomic 
force microscopy (AFM), and MTT 
cytotoxicity experiments in order to verify if 
the peptides do not aggregate in isolation and if 
they are able to reduce aggregation and/or 
breakdown preformed fibrils to a non-toxic 
species.  
 
Continuous growth ThT experiments 
demonstrate a significant reduction in fibril 
load – To determine the ability of PCA derived 
peptides to reduce fibril assembly (inhibition) 
and/or breakdown preformed fibrils (reversal), 
ThT binding was used to quantify amyloid 
species. Firstly, α-syn was rendered monomeric 
(9) and aggregated into amyloid by 
resuspending and incubating at 37C. For the 
continuous growth assay, peptides were added 
at time zero and a reading taken every five 
minutes over a 75 hour period. The ThT signal 
was significantly reduced at a 1:1 molar ratio 
indicating that the peptides is able to bind α-syn 
and reduce aggregation levels. At increasingly 
lower sub-stoichiometric ratios, we observed 
progressively reduced activity consistent with a 
general dose dependency. The control peptide 
71-82W as well as the wild-type 45-54 
sequence at 1:1 molar rations had no effect 
upon aggregation demonstrating α-syn 
specificity for the 45-54W peptide. 
 
Atomic Force Microscopy indicates a large 
reduction in amyloid levels – As a second 
direct qualitative measure of fibril formation 
samples used in continuous growth experiments 
were imaged using AFM (Figure 3b-f). A 
stoichiometry of 1:1 (450 µM:450 µM) was 
chosen for AFM experiments as this was found 
to be the most effective in ThT experiments 
(Figure 3b). At this stoichiometry a major 
reduction in the amount of amyloid was 
observed relative to the α-syn control across 
several time points (Figure 3d). No fibrils were 
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observed for the 45-54W peptide in the absence 
of α-syn. The control peptide 71-82W as well 
as the wild-type 45-54 sequence had no effect 
upon fibril formation (Figures 3e-f) supporting 
α-syn specificity for the 45-54W peptide. 
 
Circular Dichroism demonstrates a large 
reduction in β-sheet content – Since amyloid 
fibrils are predominately β-sheet, we also used 
CD spectroscopy to provide structural 
characterisation of the aggregates through the 
ThT continuous growth experiments. The data 
presented in Figure 4a show spectra over 17 
time points of the continuous growth assay. A 
single negative peak at 218nm develops across 
the time course along with the loss of minima at 
~200nm, consistent with the gain of β-sheet 
structure and the loss of a random coil. As 
predicted from the ThT data above the β-
structure did not form for the α-syn incubated 
with 45-54W at a 1:1 stoichiometry sample 
(Figure 4b). In addition, the minima at ~200nm 
did not significantly diminish. A similar 
spectrum was observed for 45-54W alone (i.e 
0:1 stoichiometry) after 75 hours of incubation, 
indicating that this peptide does not aggregate 
in isolation. The lack of CD signal intensity at 
218nm for α-syn incubated with the 45-54W 
peptide is unlikely to be attributed to increased 
aggregation or precipitation. This is because 
any peptides causing increased precipitation 
would also generate large increases in ThT 
binding and would be clearly observed in AFM 
imaging experiments. Neither the wild-type 45-
54 α-syn sequence nor the 71-82W had any 
effect upon the conversion to the β-structure 
(Figure 4c-d), again demonstrating α-syn 
specificity for the 45-54W peptide. 
 
MTT studies demonstrate reduced amyloid 
toxicity to cells – MTT ((3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide)) cell toxicity experiments were 
performed using Rat phaeochromocytoma 
(PC12) neuronal-like cells to assess toxicity of 
α-syn and the preventative effects of the 45-
54W peptide generated in this study. MTT 
assays (Figure 5a) were performed at a α-syn : 
45-54W ratio of 1:1 and presented as raw A570 
signal. At this stoichiometry, 45-54W improved 
cell viability by 65-85% relative to α-syn in 
isolation. Dose dependency experiments 
demonstrated that at molar ratios of 1:0.01 or 
1:0.1 there was no effect on toxicity. At 1:0.5 
the recovery was improved, maximizing at 1:1 
and becoming less pronounced at increasingly 
higher molar ratios (Figure 5b). In addition, 
MTT experiments using samples taken 
throughout the continuous growth experiment 
demonstrated that α-syn becomes progressively 
more toxic with time and is most toxic within 
the stationary phase of fibril growth (Figure 
5c). As predicted from ThT, CD and AFM 
experiments, MTT experiments using 45-54wt 
or 71-82W demonstrate that although these 
peptides are not toxic in isolation, they have 
very little effect upon α-syn toxicity (Figure 
5d). Finally, increasing concentrations of 45-
54W in isolation demonstrate that it is not 
toxic.  
 
SDS-PAGE analysis demonstrates that 45-
54W is able to interact with α-syn and lower 
oligomeric state  –  A range of samples were 
taken from the endpoint (75 h) of continuous 
growth experiments and subjected to ADS-
PAGE analysis (Figure 6). Two clear bands at 
~40 KDa and ~60 KDa (as determined by graph 
analysis of log MW vs. relative migration 
distance; data not shown) were found to be 
present within the 1:0 sample as well as 1:0.01, 
1:0.1, 1:2 and to a lesser extent the 1:5 sample, 
suggesting the presence of α-syn trimers 
(40/14.5 = 2.8) and tetramers (60/14.5 = 4.1). 
No bands corresponding to dimers or 5-8mers 
were observed. At a molar ratio of 1:1 or higher 
these bands were found to absent and are 
replaced by the presence three low molecular 
weight bands. One band at ~15 KDa may 
represent the α-syn:45-54W complex. The 
second and third bands are below the resolution 
limit of the gel but are likely to represent 
momomeric α-syn (14.5 KDa) and the inhibitor 
alone (1 KDa). NAlthough under denaturing 
conditions (which therefore precludes more 
detailed interpretation), this experiment 
demonstrates that 45-54W is able to interact 
with α-syn and lower the oligomeric state, 
possibly to the momomer.  
 
DISCUSSION 
 
In conclusion, we have employed semi-rational 
design combined with intracellular PCA to 
demonstrate this as an effective methodology 
for developing α-syn aggregation antagonists. 
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To date, the majority of β-sheet breaker 
compounds are either designed to target or are 
based specifically on the 71-82 region of the 
protein, since this is known to aggregate in 
isolation and therefore thought to be 
responsible for instigating amyloidosis of the 
parent protein. Inhibitors include N-methylated 
derivatives of the same sequence (9), single 
chain antibodies (31), and small molecule 
compounds such as curcumin (32) and 
epigallocatechin gallate (33).  
 In contrast, our approach has focused 
on the development of a library centered on the 
45-54 region in which four of the five known α-
syn familial mutants implicated in early onset 
PD are found. All of the known mutations in 
this region result in either increased α-syn 
aggregation rates or increased numbers of 
oligomers and therefore increased levels of 
toxicity. All residues in the 45-54 sequence 
were therefore scrambled to give two, three, or 
six options, giving rise to a library of 209,952 
members (See Figure 1). This was constructed 
to include all wild-type options as well as the 
mutations found in E46K, A53T and H50Q 
respectively. Half of the ten positions re-
selected the wild-type residues while the 
remaining five resulted in new selections. 
These were E46D, V48I, H50N, A53K and 
T54A. In amyloid inhibition experiments (i.e. 
inhibitor and monomeric α-syn mixed at time 
zero and amyloid growth continuously 
monitored) and at a stoichiometry of 1:1, we 
observe that the classical sigmoidal amyloid 
growth for an inhibitor free (1:0) sample is 
abolished. Rather, the signal is held at ~8% of 
the signal observed in the stationary phase of 
the 1:0 sample. At a stoichiometry of 1:0.5 
amyloid growth is significantly slower, taking 
approximately twice as long for the 
fluorescence intensity to match that of the 1:0 
sample. In accordance with an expected dose 
dependency, at 1:0.1 stoichiometry or lower the 
inhibitory effect is lost. The impressive efficacy 
of the 1:1 sample in continuous growth ThT 
experiments is supported by both CD data 
which show that the conversion from a random-
coil like structure consistent with native α-syn 
to a classical amyloid β-sheet signal does not 
occur in the 1:1 sample, and MTT data which 
show that toxicity associated with a-syn 
aggregation is almost completely reversed in 
the presence of 45-54W. Moreover, a clear 
reduction to almost no fibrils is observed by 
direct AFM imaging. This is corroborated by 
SDS-PAGE experiments that shows the loss of 
low molecular weight oligomers in the presence 
of 45-54W at 1:1 stoichiometry or higher.  
We have designed a library based on 
the 45-54 region of wild-type α-syn, and have 
created a potent peptide inhibitor of 
aggregation. In the future nit may be possible to 
derive more potent inhibitors of the mutagenic 
versions of α-syn that are in-turn more effective 
with the wild-type protein. Not only does this 
point towards a new target for the design of 
new inhibitors, the peptide derived here using 
PCA has the potential itself to be modified into 
drugs to slow or even prevent the onset of 
Parkinson’s disease. 
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FIGURE LEGENDS 
Figure 1: a) shown are residues 45-54 of wild-type α-syn (KEGVVHGVAT) as well as the three well 
studied point mutation sites (46, 50 and 53). Degenerate codons for library construction are shown 
below (R=A/G, V=A/C/G, W=A/T, B=C/G/T, and H=A/C/T). b) shown are amino acid options at each 
position to generate a 209,952 member peptide library. The wild-type residue options (top line) as well 
as alternative options, including those point mutations associated with early onset PD (shown in bold) 
were also considered in the library design. c) The winner peptide (KDGIVNGVKA) emerged from 
single step selection followed by two rounds of competition selection PCA.  
Figure 2:  a) Protein-fragment Complementation Assay: Peptide library members that bind to wild-type 
α-syn1-140 recombine murine DHFR and lead to colonies under selective conditions (bacterial DHFR is 
specifically inhibited using trimethoprim). Those peptides that bind with highest affinity to the α-syn 
target are able to confer cell growth by i) reconstituting mDHFR to restore activity and ii) reducing the 
toxicity associated with any given oligomeric amyloid state. In competition selection, subsequent 
passages in liquid media isolate potential winners with highest efficacy. Since PCA is performed in the 
cytoplasm of E.coli, the non-specific, unstable, aggregation prone (insoluble), protease susceptible 
members are removed. b) DNA sequencing results of library pools for passages 0-6. Both single step 
selection (P0) and competition selection (P1, P2 and P6) are shown. The peptide sequence 
KDGIVNGVKA was seen to dominate from P2 onwards. 
Figure 3 a) Continuous ThT growth: The data shows a significant reduction in ThT signal (~92%) at a 
1:1 stoichiometry.  The ThT signal at a molar ratio of 1:0.5 shows that the amyloid growth rate is 
significantly reduced compared to wild-type. At increasingly sub-stoichiometric ratios, the ThT 
fluorescence indicates reduced peptide activity in an expected dose dependent manner. Peptide 45-54W 
alone (0:1) shows no ThT binding indicating that it does not aggregate in isolation. Aliquots of samples 
were collected at 17 different time points for 1:0 (lag phase: T0, T1; exponential phase: T3, T7, T14 and 
stationary phase: End are shown) and 3 time points for 1:1 (T0, T1 and End) for further analysis using 
AFM and CD.  b) AFM images showing the endpoint samples (75 hours) for all stoichiometries used in 
continuous ThT growth experiments. A considerable reduction in fibril load is observed at a molar ratio 
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of 1:1. All other stoichiometries showed no major reduction of amyloid content relative to 1:0. The 45-
54W peptide (0:1) demonstrates that this peptide does not aggregate in isolation. c) AFM images 
showing the gradual increase of amyloid content along various time points for 1:0. Shown are six 
samples (T0-T16) taken taken from lag, exponential and stationary phase. The time points these were 
T0=0 hr, T1=10 hrs, T3=33.3hrs, T7=37.5 hrs, T14=49 hrs and End=75 hrs. d) A large reduction in 
amyloid content was observed for the for 1:1 sample with 45-54W.  For these images T0=0 hr, T1= 37.5 
hrs and T2= 75 hrs. e) No reduction in amyloid content was observed for the 1:1 sample with wild-type 
45-54.  For these images T0=0 hr, T1= 33.75 hrs and T2= 75 hrs. f) No reduction in amyloid content 
was observed for for 1:1 sample with 71-82W.  For these images T0=0 hr, T1= 28.75 hrs and T2= 75 
hrs. For all samples, many numbers of images were taken at each time point in order to confirm the 
morphology and number of fibrils present in each image. 
Figure 4 a) CD spectra using the same samples used in ThT and AFM experiments. Shown is the 
gradual development of a minima at 218nm across the time course along with the loss of a minima at 
200nm, consistent with the gain of β-sheet structure and the loss of a random coil in the 1:0 sample. b) 
In the 1:1 samples, the minima at ~200 nm was prominent even after 75 hours of incubation with no 
development of a 218 nm signal, confirming the efficacy of the 45-54W peptide in preventing the 
formation of β-sheet structure. A similar spectrum was obtained for the peptide 45-54W (0:1), 
confirming that the peptide does not adopt a β-sheet structure in isolation. c) A 1:1 sample with the 45-
54 wild-type sequence had no effect upon the conversion on β-sheet structure and the loss of a random 
coil. The 45-54 wild-type sequence in isolation (0:1) did not adopt a β-sheet structure in isolation.  d) 
Similarly, a PCA derived peptide based on the 71-82 region of α-syn had no effect upon the conversion 
on β-sheet structure and the loss of a random coil. Again the 71-82W sequence in isolation (0:1) did not 
adopt a β-sheet structure in isolation.   
Figure 5 MTT cytotoxicity assays using rat pheochromocytoma (PC12) cells, α-syn, and the inhibitory 
effect of 45-54W peptide on α-syn aggregation. a) Shown from left to right are i) PC12 cells only, ii) 
PC12 cells plus buffer, iii) PC12 cells plus buffer and ThT, iv) PC12 cells plus α-syn (5uM) in buffer, v) 
PC12 cells plus α-syn (5uM) in buffer plus ThT and vi) α-syn with 45-54W at a 1:1 stoichiometry. The 
latter leads to a large restoration of activity (~85%). b) Increasing molar ratios of α-syn:45-54W 
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demonstrates a dose dependency. Samples are taken from the endpoint of the continuous growth 
experiment (75 h) and show that no effect upon toxicity is observed at 1:0.01 or 1:0.1 and that a molar 
ratio of 1:0.5 is needed to partially rescue the cells (~28% recovery) from the cytotoxic effect of α-syn. 
This increases at 1:1 (~63%) and becomes progressively less pronounced at increasingly higher molar 
ratios. c) The effect of incubation time on toxicity using samples taken directly from the continuous 
growth experiment. Results demonstrate that toxicity progressively increases as the sample ages and is 
at its maximum within the stationary phase of the continuous growth. d) Increasing concentrations of 
45-54W demonstrates that the peptide in isolation is not toxic to PC12 cells. MTT experiments using 
45-54wt (bold surround) or 71-82W (hashed surround) demonstrate that the peptide are not toxic in 
isolation but at a ratio of 1:1 with α-syn have almost no effect upon toxicity. All experiments were 
undertaken in triplicate and errors are shown as the standard deviation. 
Figure 6: SDS-PAGE analysis shows a range of samples taken from the endpoint (75 h) of continuous 
growth experiments. Two clear bands at ~40 KDa and ~60 KDa (as determined by graph analysis of log 
MW vs. relative migration distance) are present within the 1:0 sample as well as 1:0.01, 1:0.1, 1:2 and 
1:5 samples, suggesting the presence of α-syn trimers (40/14.5 = 2.8) and tetramers (60/14.5 = 4.1). At 
molar ratios of 1:1 or higher these bands are absent and are replaced by the presence three low 
molecular weight bands. One band at ~15 KDa may represent the α-syn:45-54W complex. The second 
and third bands are below the resolution limit of the gel but are likely to represent momomeric α-syn 
(14.5 KDa) and the inhibitor alone (1 KDa).   
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